Results 171 to 180 of about 2,657,421 (309)

Development of Cathepsin B‑Activatable Cell-Penetrating Peptides for Tumor Targeting. [PDF]

ACS Pharmacol Transl Sci
Kuhne K, Strohbach L, Neuber C, Wodtke R, Ruiz-Gómez G, Belter B, Brandt F, Gluhacevic von Krüchten L, Keller M, Pisabarro MT, Kopka K, Pietzsch J, Löser R.   +12 more
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Migrasome-mediated clearance of PLK4: a novel mechanism for centrosome homeostasis and tumor targeting. [PDF]

EBioMedicine
Zhao Z, Song Y.
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Targeting molecular tumor types [PDF]

Nature Genetics, 2013
openaire   +2 more sources

Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles. [PDF]

Drug Des Devel Ther
Parang K, Do T, Dinh C, Davani-Davari D, Foroughi M, Khong T, Moazen M, Nasrolahi Shirazi A.   +7 more
europepmc   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Newsletter: A Report to the Physicians of Texas

, 1980
Quarterly newsletter from the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute discussing cancer care and research to inform physicians of recent developments in the ...
McBurney, Marcia K., M.D. Anderson Hospital and Tumor Institute   +1 more
core  

Erratum: Improved Tumor Targeting and Longer Retention Time of NIR Fluorescent Probes Using Bioorthogonal Chemistry: Erratum. [PDF]

Theranostics
Zhang X, Wang B, Zhao N, Tian Z, Dai Y, Nie Y, Tian J, Wang Z, Chen X.   +8 more
europepmc   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source